Dostarlimab Plus Chemotherapy Is Cost Effective, Improves QOL for Endometrial Cancer Patients

The addition of dostarlimab to platinum chemotherapy is cost effective and significantly improves quality of life in patients with endometrial cancer, according to a study published in Gynecologic Oncology.

While the combination of dostarlimab with carboplatin and paclitaxel has demonstrated improved progression-free survival and overall survival in primary advanced and recurrent endometrial cancer, past studies have not found this combination to be cost effective, or to be cost effective only in certain groups. Therefore, this study aimed to assess the cost-effectiveness of combination therapy compared with chemotherapy alone.

Researchers developed a survival model to compare the cost and effectiveness of dostarlimab in combination with chemotherapy compared with chemotherapy alone in primary advanced or recurrent endometrial cancer. Clinical data were derived from the RUBY trial, and drug costs were derived from average sale prices. Researchers analyzed the incremental cost-effectiveness ratio to compare a set willingness to pay of $100,000/quality-adjusted life-year (QALY) to determine cost-effectiveness.

According to the results, the dostarlimab combination incurred an additional cost of $308,430 in the intention-to-treat population; however, it provided an additional 5.67 QALYs compared with chemotherapy alone. “Despite the higher cost, adding dostarlimab to platinum chemotherapy significantly improves QALYs, rendering this regimen cost effective relative to chemotherapy alone for treating primary advanced or recurrent endometrial cancer. Combination therapy is a cost-effective approach for this patient population compared with chemotherapy alone,” the researchers concluded.

Follow us on X/Twitter: @mydocwire